← All trials
NCT05183646
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 30, 2022
- Primary completion
- Jun 30, 2024
- Completion date
- Jun 30, 2026
- First posted
- Jan 10, 2022
- Last posted
- Jul 25, 2022
- Enrollment
- 286
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Dimerix Bioscience Pty LtdLead sponsor
- Dimerix Bioscience Pty LtdStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.